Midas Research Initiates Coverage of CEL-SCI VIENNA, Va., March 29 /PRNewswire-FirstCall/ -- Midas Research of Germany has published a research report on the biotechnology company CEL-SCI Corporation (Amex: CVM; Germany: LSR.FSE) with a 12 month target of $2.80 and a strong speculative buy recommendation. A copy of the report is available in both German and English at http://www.midasresearch.de/. Midas Research is an independent stock research company led by Michael Drepper, formerly one of thefirst internationally ranked German analysts. He was both the Deputy Head of European Research of Dresdner Kleinwort as well as the Head of Research and Director of Consors Capital Bank AG, a subsidiary of a leading German internet broker. As judged by its track record since the company's inception in 2002, Midas Research has been particularly successful in its recommendations in the biotechnology field (e.g., Immtech, Response Biomedical and Morphosys). The views and opinions in this report are solely those of the author of the report. CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. DATASOURCE: CEL-SCI Corporation CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460 Web site: http://www.cel-sci.com/ http://www.midasresearch.de/

Copyright